Gregory Tesz Ph.D. is an Associate Research Fellow in the Pfizer Internal Medicine Research Unit. At Pfizer, his work has focused on understanding the underlying metabolic dysfunctions of both Nonalcoholic Fatty Liver Disease and Type 2 diabetes in order to inform and develop novel therapies for these diseases. Understanding how abnormal hepatic carbohydrate and lipid metabolism drive steatosis, insulin resistance, and hepatic inflammation has been a goal of Gregory’s research.
At Pfizer, he has led the biology research efforts on a number of pre-clinical and clinical stage programs. Gregory received his Ph.D. from the University of Massachusetts Medical School having studied the interplay of inflammation and metabolic homeostasis. His broad range of experience includes preclinical model expertise, preclinical drug development and novel clinical strategies for assessing target engagement.